Upadacitinib in Ulcerative Colitis and Crohn's Disease Remission

Clinical remission outcomes upadacitinib ulcerative colitis Crohn disease

The clinical remission data on upadacitinib across UC and Crohn's disease are now substantial, built on five phase 3 RCTs and supported by a long-term extension and a growing real-world body of evidence.

Ulcerative Colitis

The two phase 3 induction trials — U-ACHIEVE and U-ACCOMPLISH — both used upadacitinib 45 mg once daily for 8 weeks versus placebo. In U-ACHIEVE, clinical remission per adapted Mayo Score was achieved in 26.1% with upadacitinib versus 4.8% with placebo. In U-ACCOMPLISH, the rates were 33.5% versus 4.1%. Remission rates in biologic-naïve patients were considerably higher (around 35–38%) than in biologic-inadequate responders (18–30%), though even the latter group showed a clear and significant benefit over placebo. Clinical response emerged as early as week 2 in about 60% of upadacitinib-treated patients versus 27% on placebo, which is notably fast.

For maintenance in UC (U-ACHIEVE Maintenance), clinical responders were re-randomized to 15 mg, 30 mg, or placebo for 52 weeks. Both maintenance doses maintained efficacy significantly above placebo, with 30 mg numerically outperforming 15 mg on most endpoints. A 2025 long-term extension interim analysis from U-ACTIVATE found that among patients who had already completed 52 weeks of maintenance, 71–76% were still in clinical remission at week 48 and 74–76% at week 96 of the extension (as-observed population), with about 80–84% maintaining remission among those who entered the extension already in remission. Endoscopic remission tracked lower, around 45–49% at week 48 and week 96 of the extension.

Crohn's Disease

The U-EXCEL and U-EXCEED induction trials (12 weeks of 45 mg, published in NEJM 2023) showed clinical remission by CDAI in 49.5% vs. 29.1% in U-EXCEL and 38.9% vs. 21.1% in U-EXCEED, with endoscopic response — a co-primary endpoint — achieved in 45.5% vs. 13.1% (U-EXCEL) and 34.6% vs. 3.5% (U-EXCEED). The higher CDAI remission rate in placebo groups here (21–29%) compared to UC induction trials reflects the well-known placebo response pattern in Crohn's disease. Symptom improvement in CD was rapid, with clinical remission observable as early as days 5–6 after starting treatment.

The full U-ENDURE maintenance population (673 patients) showed CDAI clinical remission at week 52 in 51.5% with 30 mg and 36.2% with 15 mg, compared to 15.2% with placebo. Endoscopic response at week 52 was 40.7% (30 mg), 27.3% (15 mg), and 7.2% (placebo). The dose-dependency is clear: upadacitinib 30 mg consistently outperforms 15 mg in CD maintenance across clinical and endoscopic endpoints.

For perianal fistulizing CD, a post hoc analysis of the phase 3 trials found that drainage resolution in perianal fistulas occurred in 44.7% with upadacitinib 45 mg versus 5.6% with placebo at the end of induction, a striking difference despite small subgroup sizes.

Cross-Disease Meta-Analysis

A meta-analysis of nine RCT and real-world studies pooled clinical remission across IBD: 36% in RCTs (95% CI 30–42%), with clinical response of 61% in RCTs. A 2026 network meta-analysis comparing JAK inhibitors ranked upadacitinib highest for endoscopic remission and endoscopic response across IBD, with moderate ranking for clinical remission overall.

Safety

Across RCTs, serious adverse event rates were not significantly elevated compared to placebo (upadacitinib 6.1% vs. placebo 7.0%), and anemia and arthralgia were actually reduced with upadacitinib. The established concerns are neutropenia and creatine kinase elevation (both significantly more frequent with upadacitinib), and a dose-dependent increase in herpes zoster, particularly at the 30 mg and 45 mg doses. Hepatic disorders were more frequent at higher doses in CD. No meaningful signal for major cardiovascular events, venous thromboembolism, or lymphoma emerged across the phase 3 trials.

These results are from the core phase 3 program; the real-world evidence base is still developing, and longer-term safety data, especially for the 30 mg maintenance dose, will be important to watch.